EGFR-IN-44

EGFR-IN-44 (Compound 6a) is a potent, orally active EGFR tyrosine kinase inhibitor with an IC50 of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfr-in-44.html

Solubility

10 mM in DMSO

Smiles

C=CC(NC1=CC(NC2=NC(C3=CSC4=CC=CC=C43)=C(C=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)=O

Molecular Formula

C27H29ClN6O2S

Molecular Weight

537.08

References & Citations

[1]Baijiao An, et al. Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Bioorg Chem. 2022 May;122:105743.